Patients with inoperable, early-stage lung cancer who receive stereotactic body radiation therapy have 40% five-year survival rate

Patients with inoperable, early-stage lung cancer who receive stereotactic body radiation therapy (SBRT) have a five-year survival rate of 40 percent, according to new research.